Literature DB >> 11810504

Activities of beta-lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination against Pseudomonas aeruginosa isolated from complicated urinary tract infections.

H. Hayami1, Toshihiro Goto, Motoshi Kawahara, Yoshitada Ohi.   

Abstract

Using the checkerboard titration method as well as the time-kill curve technique, we investigated the activities of beta-lactams, fluoroquinolones, amikacin, and fosfomycin alone and in combination against Pseudomonas aeruginosa isolated from patients with complicated urinary tract infections. In the checkerboard titration studies, none of 21 combinations demonstrated antagonism against 26 strains tested, and the mean fractional inhibitory concentration (FIC) indices for these combinations ranged between 0.4694 and 0.9828. Corresponding to the respective FIC indices, the bactericidal activity determined in combinations of meropenem with ciprofloxacin or amikacin and ceftazidime with ciprofloxacin at sub-minimum inhibitory concentrations (MICs) produced a great reduction in bacterial counts (>/=2 log10 CFU/ml) within 6 h of administration against most of the strains, including strains resistant to one or both drugs, and these synergistic effects were confirmed morphologically by scanning electron microscopy. In time-lag combinations, the first administration of ciprofloxacin or amikacin supplemented by meropenem with 1-h lag diminished bactericidal activity, in comparison with the simultaneous administration of the drugs. These results suggest that simultaneous combinations of beta-lactams with fluoroquinolones or amikacin may be useful alternatives for the treatment of serious infections due to P. aeruginosa.

Entities:  

Year:  1999        PMID: 11810504     DOI: 10.1007/s101560050022

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  6 in total

1.  Synergy of drug combinations in treating multidrug-resistant Pseudomonas aeruginosa.

Authors:  Meher Rizvi; Junaid Ahmad; Fatima Khan; Indu Shukla; Abida Malik; Hiba Sami
Journal:  Australas Med J       Date:  2015-01-31

2.  Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Authors:  Antonia C Kastoris; Petros I Rafailidis; Evridiki K Vouloumanou; Ioannis D Gkegkes; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2010-02-26       Impact factor: 2.953

3.  Structural changes and differentially expressed genes in Pseudomonas aeruginosa exposed to meropenem-ciprofloxacin combination.

Authors:  Vera Lúcia Dias Siqueira; Rosilene Fressatti Cardoso; Katiany Rizzieri Caleffi-Ferracioli; Regiane Bertin de Lima Scodro; Maria Aparecida Fernandez; Adriana Fiorini; Tania Ueda-Nakamura; Benedito Prado Dias-Filho; Celso Vataru Nakamura
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

Review 4.  Multidrug-resistant Gram-negative infections: what are the treatment options?

Authors:  Helen Giamarellou; Garyphallia Poulakou
Journal:  Drugs       Date:  2009-10-01       Impact factor: 9.546

5.  Morphological analysis of the antimicrobial action of nitric oxide on gram-negative pathogens using atomic force microscopy.

Authors:  Susan M Deupree; Mark H Schoenfisch
Journal:  Acta Biomater       Date:  2009-01-31       Impact factor: 8.947

6.  Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.

Authors:  David L MacLeod; Lynn M Barker; Jennifer L Sutherland; Suzanne C Moss; Jesse L Gurgel; Thomas F Kenney; Jane L Burns; William R Baker
Journal:  J Antimicrob Chemother       Date:  2009-08-13       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.